SynthesisCardiovascular diabetology2025
Effect of SGLT2 inhibitors on cardiac structure and function assessed by cardiac magnetic resonance: a systematic review and meta-analysis.
Synthesis in Cardiovascular diabetology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Association of SGLT2 Inhibitor Use with All-Cause Mortality Following CIED Implantation for Conduction Disease in Patients with Preserved LVEF: A Retrospective Cohort Study.Journal of clinical medicine · 2026Article
- Empagliflozin Attenuates Cardiac Dysfunction in Rat Model of Metabolic Syndrome: Evaluating Role of the Cardiac Renin-Angiotensin System.Biomedicines · 2026Article
- Empagliflozin Protects Against Doxorubicin Cardiotoxicity: Integrative Assessment of Cardiac Kinetics and Electrophysiology Using Machine Learning in a Rat Model.Medical sciences (Basel, Switzerland) · 2026Article
- Mechanisms and Therapeutic Potential of Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure.Reviews in cardiovascular medicine · 2026Review
- Impact of an assessment form on promoting in-hospital initiation of sodium-glucose cotransporter-2 inhibitors in hospitalized patients with heart failure.International journal of cardiology. Cardiovascular risk and prevention · 2026Article
- Patterns in Prescribing and Predictors of SGLT2 Inhibitor Administration in Patients with Heart Failure and Acute Myocardial Infarction: A Real-World Retrospective Cohort Study.Journal of clinical medicine · 2026Article
- Vascular and Myocardial Function in Patients with Type 2 Diabetes and Ischemic Stroke Treated with Dulaglutide or Empagliflozin.Medicina (Kaunas, Lithuania) · 2026Article
- Early SGLT2 Inhibitor Therapy in Acute Coronary Syndrome: Mitigating Adverse Remodeling in High-Risk Phenotypes-A Real-World Study.Medicina (Kaunas, Lithuania) · 2026Observational
- Right ventricular dysfunction in type 1 diabetic cardiomyopathy: An overlooked component?World journal of diabetes · 2026Article
- The impact of metformin on myocardial hypertrophy: an updated systematic review, meta-analysis, and meta-regression of randomized controlled trials.Diabetology & metabolic syndrome · 2025Review
- Arrhythmia-Induced Cardiomyopathy in Atrial Fibrillation: Pathogenesis, Diagnosis, and Treatment.Life (Basel, Switzerland) · 2025Review
- SGLT2 Inhibitors in the Management of Cardio-Renal-Metabolic Syndrome: A New Therapeutic Era.Medicina (Kaunas, Lithuania) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
BACKGROUND AND
aimSodium-glucose cotransporter-2 inhibitors (SGLT2i) improve outcomes in patients with heart failure (HF) but underlying mechanisms remain incompletely understood. Cardiac magnetic resonance (CMR) is key in evaluating cardiac structure and function, enabling accurate assessment of reverse remodeling. Aim of this systematic review and meta-analysis was to assess the effects of SGLT2i on cardiac remodeling evaluated by CMR changes.
methodsWe conducted a systematic review and meta-analysis of studies assessing changes in CMR parameters in patients treated with SGLT2i (PROSPERO registration: CRD42024574302). Databases were searched through April 30, 2025. Random-effects models were used to pool mean changes in left and right ventricular volumes, mass, function, stroke volume, global longitudinal strain, left atrial volume, and tissue characterization indices. Meta-regression and sensitivity analyses were performed to evaluate potential sources of heterogeneity.
resultsTwenty-three studies and 1008 patients were included. Treatment with SGLT2i was associated with significant reductions in left ventricular (LV) end-diastolic volume (- 7.10 mL; 95% CI: -13.01 to - 1.19, p = 0.023), left ventricular mass (- 4.24 g; 95% CI: -7.88 to - 0.60, p = 0.027) and epicardial adipose tissue (-4.94 ml; 95% CI: -9.06, -0.82, p = 0.019). A subgroup analysis in patients with reduced LV ejection fraction showed improvement in LV stroke volume. Meta-regression revealed no significant effect of age, male sex or diabetes prevalence on pooled estimates.
conclusionsSGLT2i are associated with reductions in LV volumes and mass in line with an overall favorable reverse remodeling effects as assessed by CMR.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.